United States · FDA National Drug Code directory
Reblozyl
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 59572-711_769ec39a-61bd-4726-b14a-9594897baa67
- Product NDC
- 59572-711
- Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Composition / generic term
- Luspatercept
- Labeler
- Celgene Corporation
- Marketing category
- BLA
- Marketing start / end (source format)
- 20191108
- Source listing expiry
- 20271231
Source-listed ingredients
- LUSPATERCEPT — 25 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 1 VIAL, GLASS in 1 CARTON (59572-711-01) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, GLASS · 59572-711-01
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →